GOSS
Price
$1.72
Change
-$0.02 (-1.15%)
Updated
Aug 8, 10:37 AM (EDT)
Capitalization
392.1M
90 days until earnings call
ZVRA
Price
$11.86
Change
-$0.27 (-2.23%)
Updated
Aug 8, 11:00 AM (EDT)
Capitalization
663.26M
4 days until earnings call
Interact to see
Advertisement

GOSS vs ZVRA

Header iconGOSS vs ZVRA Comparison
Open Charts GOSS vs ZVRABanner chart's image
Gossamer Bio
Price$1.72
Change-$0.02 (-1.15%)
Volume$12.4K
Capitalization392.1M
Zevra Therapeutics
Price$11.86
Change-$0.27 (-2.23%)
Volume$200
Capitalization663.26M
GOSS vs ZVRA Comparison Chart in %
Loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GOSS vs. ZVRA commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and ZVRA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (GOSS: $1.73 vs. ZVRA: $12.13)
Brand notoriety: GOSS and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 133% vs. ZVRA: 147%
Market capitalization -- GOSS: $392.1M vs. ZVRA: $663.26M
GOSS [@Biotechnology] is valued at $392.1M. ZVRA’s [@Biotechnology] market capitalization is $663.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, ZVRA is a better buy in the long-term than GOSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 2 TA indicator(s) are bullish while ZVRA’s TA Score has 3 bullish TA indicator(s).

  • GOSS’s TA Score: 2 bullish, 6 bearish.
  • ZVRA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ZVRA is a better buy in the short-term than GOSS.

Price Growth

GOSS (@Biotechnology) experienced а -15.44% price change this week, while ZVRA (@Biotechnology) price change was +9.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.22%. For the same industry, the average monthly price growth was +6.60%, and the average quarterly price growth was +12.79%.

Reported Earning Dates

GOSS is expected to report earnings on Nov 06, 2025.

ZVRA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+0.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZVRA($663M) has a higher market cap than GOSS($392M). GOSS YTD gains are higher at: 90.692 vs. ZVRA (45.444). GOSS has higher annual earnings (EBITDA): -35.7M vs. ZVRA (-60.3M). GOSS has more cash in the bank: 258M vs. ZVRA (62.6M). ZVRA has less debt than GOSS: ZVRA (61.8M) vs GOSS (203M). GOSS has higher revenues than ZVRA: GOSS (125M) vs ZVRA (40.6M).
GOSSZVRAGOSS / ZVRA
Capitalization392M663M59%
EBITDA-35.7M-60.3M59%
Gain YTD90.69245.444200%
P/E RatioN/AN/A-
Revenue125M40.6M308%
Total Cash258M62.6M412%
Total Debt203M61.8M328%
FUNDAMENTALS RATINGS
GOSS vs ZVRA: Fundamental Ratings
GOSS
ZVRA
OUTLOOK RATING
1..100
7121
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
85
Overvalued
PROFIT vs RISK RATING
1..100
10062
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3539
P/E GROWTH RATING
1..100
10027
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (57) in the Pharmaceuticals Major industry is in the same range as ZVRA (85) in the null industry. This means that GOSS’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Profit vs Risk Rating (62) in the null industry is somewhat better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that ZVRA’s stock grew somewhat faster than GOSS’s over the last 12 months.

ZVRA's SMR Rating (100) in the null industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that ZVRA’s stock grew similarly to GOSS’s over the last 12 months.

GOSS's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as ZVRA (39) in the null industry. This means that GOSS’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's P/E Growth Rating (27) in the null industry is significantly better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that ZVRA’s stock grew significantly faster than GOSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GOSSZVRA
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 12 days ago
83%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 11 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
72%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CPODX57.71N/A
N/A
Morgan Stanley Insight I
RSPYX30.34N/A
N/A
Victory RS Partners Y
BGRFX81.67N/A
N/A
Baron Growth Retail
MAIJX19.29N/A
N/A
Morgan Stanley Inst Passport ovrs eq R6
MSDMX14.01N/A
N/A
Morgan Stanley Emerging Mkt ex China R6

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with MEIP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then MEIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
-12.88%
MEIP - GOSS
46%
Loosely correlated
+2.41%
ABEO - GOSS
42%
Loosely correlated
-1.88%
APVO - GOSS
41%
Loosely correlated
-1.38%
AUPH - GOSS
37%
Loosely correlated
-1.55%
SLDB - GOSS
37%
Loosely correlated
-7.61%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with DNTH. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then DNTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
+5.66%
DNTH - ZVRA
35%
Loosely correlated
-6.08%
COGT - ZVRA
33%
Loosely correlated
-0.82%
AXON - ZVRA
33%
Loosely correlated
+0.85%
GOSS - ZVRA
33%
Poorly correlated
-12.88%
VCYT - ZVRA
33%
Poorly correlated
+15.48%
More